Characterisitcs and Drug Utilization among Treated Chronic Hepatitis C Virus (Chc) Patients with and without Chronic Kidney Disease (Ckd) in the Us

Abstract

tion prescribed between July 2013 and June 2014. Results: Of 2,558 CHC treated patients, 142 patients (5.6%) were identified as having CKD. The mean age of CHC patients with CKD was 61 years compared to 57 years among those without CKD (p< .0001). Compared to CHC patients without CKD (n = 2,416), patients with CKD had significantly more comorbidities including diabetes (53% vs 23%, p< .0001), major depression (15% vs.6%, p= .0007), hypertension (85% vs. 51%, p< .0001) and heart failure (19% vs. 2%, p< .0001). CHC patients with CKD also had higher prevalence of kidney transplants (11% vs.1%, p< .0001) and more liver transplants (35% vs. 6%, p< .0001). For concomitant drug use, CHC patients with CKD had significantly more concomitant drugs (by drug class) during the 2-year baseline period compared to those without CKD (17 vs 11, p< .0001).

Diagnosis and treatment of chronic hepatitis C with concomitant extrahepatic manifestations deserves a closer look

“…Glomerulonephritis and membranous nephropathy not accompanied by cryoglobulinemia are rarely associated with HCV infection. [12] Since Interferon therapy may aggravate kidney diseases, a renal biopsy is usually required before starting anti-HCV treatment and determining the role of HCV in inducing membranous proliferative glomerulonephritis. Patients with significant renal histological damage require treatments combining immunosuppressants.…”